|

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)19 Protocols (14 Active Accrual of new subjects, 5 Follow-up of previously enrolled subjects)
-
08-AR-0029:
Phase Ib, MultiCenter Randomized, Double-Blind Placebo-Controlled, Dose Escalation Study w/Open-Label Extension to Evaluate Safety and Tolerability of Multiple IV Doses of MEDI-545; A Fully Human Anti-IFN-alpha Monoclonal Antibody in Patients w/SLE
-
05-AR-0014:
Continuation of a Pilot Open-Label Study of IL 1 Trap in Adult Subjects with Autoinflammatory Disease: A Therapeutic Approach to Study Pathogenesis
-
04-AR-0205:
Progression of Spinal Fusion in Ankylosing Spondylitis
-
03-AR-0298:
A Pilot Study with the IL-1 Receptor Antagonist Anakinra or Kineret in Patients with Neonatal Onset Multisystem Inflammatory Disease (NOMID/CINCA Syndrome)
-
03-AR-0173:
Studies of the Natural History and Pathogenesis of Neonatal Onset Multisystem Inflammatory Disease (NOMID)
-
03-AR-0133:
Clinically Important Changes in Rheumatoid Arthritis
-
03-AR-0131:
Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study
-
02-AR-0131:
Collection Of Blood Components Using Apheresis From Patients With Rheumatic Diseases And Healthy Volunteers
-
01-AR-0227:
Natural History of Rheumatic Disease in Minority Communities
-
00-AR-0222:
Studies of the Pathogenesis and Natural History of Arthritis and Related Conditions
-
99-AR-0004:
Molecular Basis of Primary Immunodeficiencies
-
94-AR-0105:
Genetics and Pathophysiology of Familial Mediterranean Fever and Related Disorders
-
94-AR-0066:
Studies of the Pathogenesis and Natural History of Systemic Lupus Erythematosus (SLE)
-
91-AR-0196:
Studies on the Natural History and Pathogenesis of Polymyositis, Dermatomyositis, and Related Diseases
-
08-AR-0008:
Insulin Resistance and Atherosclerosis in a Sample of Women with Systemic Lupus Erythematosus
-
03-AR-0130:
Genetic Determinants of Ankylosing Spondylitis Severity - Cross Sectional Study
-
02-AR-0272:
A Phase I, Open-Labeled, Dose-Ascending Clinical Trial of Immunotherapy of MRA, A Humanized Anti-IL 6 Receptor Monoclonal Antibody, In Patients with Systemic Lupus Erythematosus
-
02-AR-0156:
A Randomized, Double-Blind, Placebo-Controlled Trial of Infliximab In Patients With Dermatomyositis and Polymyositis
-
98-AR-0124:
Genetics of Rheumatoid Arthritis: The North American Rheumatoid Arthritis Consortium
Search The Studies | Help | Questions
| Clinical Center Home | NIH Home
National Institutes of Health Clinical Center
Bethesda, Maryland 20892. Last update: 09/17/2008
|
|